OriGene Logo
Search:    
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
 
Home About Us News & Events

spacer

Press Releases and News

divider

Rockville, MD – April 14, 2016. A pair of recently published studies shed light on the highly interesting area on detection of ALK expression among NSCLC patients by IHC. One study was conducted by NordiQC (Aalborg, Denmark),. (Full Press Release)
Rockville, MD. February 4th, 2016 – OriGene Technologies, Inc., announced today that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB™ technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene’s mouse anti-ALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.. (Full Press Release)
Rockville, MD – January 7th, 2016 - OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.. (Full Press Release)

More press release & news >>


Conferences

Where OriGene scientists are presenting their findings and new product launches
divider

Immuno oncology Summit
Aug 29-Sep 02, 2016, Boston, MA. Booth #6

NIH Research Festival
Sep 15-Sep 16, 2016, Bethesda, MD. Booth #662

SFN 2016
Nov 12-Nov 16, 2016, San Diego. Booth #502

ASCB 2016
Dec 03-Dec 07, 2016, San Francisco. Booth #319

 

 

spacer
Inc 5000 Healthcare Company
All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title